Jardiance and Ozempic are not the same medication. They belong to different drug classes, work through completely different mechanisms in the body, and are taken in different ways. Both are commonly prescribed for type 2 diabetes and both can help with weight loss, which is why they’re often confused. But the similarities are mostly surface-level.
How Each Drug Works
Jardiance (empagliflozin) is an SGLT2 inhibitor, a class of drugs that works in the kidneys. It blocks the kidneys from reabsorbing glucose back into the bloodstream, causing excess sugar to be flushed out through urine. The effect is straightforward: less sugar stays in your blood, and you lose some calories along with it.
Ozempic (semaglutide) is a GLP-1 receptor agonist, which mimics a natural gut hormone that your body releases after eating. It stimulates insulin production when blood sugar is high, slows down how quickly food leaves your stomach, and acts on appetite centers in the brain to reduce hunger. This combination of effects lowers blood sugar and significantly curbs food intake.
Pill vs. Injection
Jardiance is a daily pill taken by mouth. Ozempic is a once-weekly injection given under the skin, typically in the abdomen, thigh, or upper arm using a prefilled pen. For people who strongly prefer avoiding needles, this difference alone can be a deciding factor. There is an oral version of semaglutide (sold as Rybelsus), but Ozempic specifically is injectable.
What Each Is Approved to Treat
Both drugs are FDA-approved to improve blood sugar control in adults with type 2 diabetes as an add-on to diet and exercise. Beyond that, their approved uses diverge.
Jardiance has broader cardiovascular and heart failure approvals. It is specifically approved to reduce the risk of cardiovascular death in adults with type 2 diabetes and established heart disease, and to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure, regardless of whether they have diabetes. That heart failure indication makes it unique compared to Ozempic.
Ozempic is approved to reduce the risk of major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes and known heart disease. Semaglutide at a higher dose is also sold under the brand name Wegovy for chronic weight management, but Ozempic itself is not FDA-approved for weight loss alone.
Neither drug is recommended for type 1 diabetes. Jardiance can actually increase the risk of a dangerous condition called diabetic ketoacidosis in those patients.
Weight Loss Differences
Both medications cause weight loss, but Ozempic generally produces more. In the PIONEER 2 trial, which directly compared oral semaglutide to empagliflozin in people with type 2 diabetes, patients on semaglutide lost an average of about 10 pounds over 52 weeks compared to roughly 8 pounds for those on Jardiance. That gap may seem modest, but it tends to widen at higher doses of semaglutide and over longer treatment periods.
The weight loss mechanisms are different too. Jardiance helps you lose weight mainly by flushing out glucose (and its calories) through urine. Ozempic reduces appetite directly, so you eat less without fighting hunger as much. People on Ozempic frequently report that food simply doesn’t occupy their thoughts the way it used to.
Side Effects to Expect
The side effect profiles are almost entirely different, which makes sense given how differently these drugs work in the body.
Jardiance’s most notable side effects involve the urinary and genital tract. Because it pushes extra sugar into the urine, it creates an environment where yeast and bacteria thrive. Yeast infections are reported by roughly 20% of users, and urinary tract infections affect about 10%. Staying hydrated and practicing good hygiene can help, but these side effects are a consistent trade-off with this drug class.
Ozempic’s side effects are overwhelmingly gastrointestinal. About one in three users reports nausea, especially in the first weeks as the dose is gradually increased. Diarrhea affects around 17% of users, constipation about 16%, and vomiting about 12%. These symptoms typically improve over time as the body adjusts, but for some people they persist enough to limit the dose or stop the medication. Ozempic is not recommended for people with severe gastroparesis, a condition where the stomach already empties too slowly.
Cardiovascular and Kidney Protection
Both drugs have demonstrated meaningful heart benefits, but through what appear to be different pathways. The EMPA-REG OUTCOME trial showed that empagliflozin reduced cardiovascular death, hospitalization for heart failure, and all-cause mortality in people with type 2 diabetes and established heart disease. These heart failure benefits have since been confirmed across the entire SGLT2 inhibitor drug class in multiple large studies.
Semaglutide’s cardiovascular data comes from the SUSTAIN-6 trial, which showed reductions in heart attack and stroke risk. Notably, that trial was originally designed to prove safety rather than efficacy, making the positive results more striking. However, the heart failure benefits seen with SGLT2 inhibitors like Jardiance have not been as clearly established with GLP-1 drugs.
For kidney protection, SGLT2 inhibitors as a class have strong evidence for slowing the progression of chronic kidney disease. Jardiance is not recommended for blood sugar control in people whose kidney function has already dropped below a certain threshold (eGFR under 30), though it can still be used for heart failure at lower kidney function levels. Ozempic also shows kidney-protective signals, but empagliflozin’s renal data is more established.
Who Should Not Take Them
Ozempic carries a boxed warning related to thyroid tumors. It is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or a rare genetic condition called multiple endocrine neoplasia syndrome type 2.
Jardiance should not be used by people on dialysis. Both drugs can lower blood sugar further when combined with insulin or other diabetes medications, so doses of those other drugs sometimes need adjustment.
Can You Take Both Together?
Yes, some people take Jardiance and Ozempic at the same time. Because the two drugs work through completely independent mechanisms, combining them can offer additive benefits for blood sugar control, weight loss, and cardiovascular protection. Your prescriber might choose this approach if one medication alone isn’t achieving the target blood sugar levels, or if you have both heart failure and type 2 diabetes with cardiovascular risk factors.
Taking both does mean managing two different side effect profiles simultaneously, so the decision depends on your overall health picture and what conditions you’re treating.